Shockwave Medical projects revenue for the full year 2023 to range from $660M-$680M, which represents 35% to 39% growth over the full year 2022 revenue, the company announced last night along with its report of results for the three months and full year ended December 31, 2022.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SWAV:
- ShockWave Medical price target raised to $252 from $247 at Canaccord
- ShockWave Medical reports Q4 EPS $3.71, consensus $1.00
- Shockwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results
- ShockWave Medical announces coronary IVL included as treatment option by SCAI
- ShockWave Medical price target lowered to $280 from $300 at Piper Sandler